Obesity

Dr Chiadi Ndumele explains the need for the more comprehensive and also nuanced qualitative approach to estimating long-term CVD risk.

Your daily dose of the clinical news you may have missed.

Which hypertension treatment options should be used as first-line therapy in patients with obesity? A clinician's answer and explanation, here.

AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.

TLM 2023: In participants with metabolic dysfunction-associated steatotic liver disease, retatrutide 8 mg and 12 mg resolved steatosis in >85% of subjects.

The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.

President of the Alabama Obesity Society, Dr Jonathan Parker, discusses obesity as a risk factor for hypertension.

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

Your daily dose of the clinical news you may have missed.

Tirzepatide could help individuals who lose weight with lifestyle change to maintain and augment that loss, a well known challenge among persons with obesity.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The 2 highest doses of tirzepatide were ranked most likely to be effective for weight management in persons without diabetes, followed by semaglutide 2.4 mg.

In postmenopausal women with HR+ breast cancer who had obesity, recurrence of breast cancer while on aromatase inhibitor therapy was 18%, report investigators.

President of the Alabama Obesity Society, Dr Jonathan Parker, provides an in-depth overview of the association between obesity and hypertension.

A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.

A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.

Semaglutide treatment reduced weight and was associated with greater, more consistent improvements in HFpEF than other recently studied drug classes.

Your daily dose of the clinical news you may have missed.

Sandra Christensen, MSN, ARNP, gives her top strategies on patient selection for treatment with antiobesity medications and how to choose the right drugs for patients.

Your daily dose of the clinical news you may have missed.

Waist-to-hip ratio was more powerfully and consistently associated with risk of all-cause mortality than BMI or FMI, but can it replace BMI as a clinical indicator?

The new app is designed to help persons with diabetes understand how food and activity impact blood glucose levels and to revise behavior accordingly.

An intensive parent-support early childhood obesity intervention program led to better weight status outcomes in the long-term compared to standard therapy, report study authors.

Obesity specialist Sandra Christensen, MSN, ARNP, compares the benefits and drawbacks among older antiobesity drugs and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

Obesity specialist Sandra Christensen, MSN, ARNP, details the differences between older antiobesity medications and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

The selective aldosterone synthase inhibitor will move into late stage clinical trials, a nod to the potential for a first-in-class agent targeting aldosterone.

The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?

Your daily dose of clinical news you may have missed.

Elevated inflammation, rather than depression, may drive poor weight loss outcomes in patients with obesity following bariatric surgery, suggest authors of new study.